Specifically, our data reveal that the oxidoreductase enzyme ERO1α is a major proliferation regulator in pancreatic cancer cells both in vitro and in vivo, hence this protein may constitute a useful diagnostic marker of tumor progression and possible new therapeutic target in pancreatic malignancy. This evidence concerns the gene ERO1A and neoplasm.